Clinical Research Solutions
Feasibility Assessment
Protocol Design
Regulatory Strategy
Study Start-Up and Site Activation
Site and Project Management
Clinical Monitoring
Clinical Data Management
We advance evidence-based medicine with high-quality clinical research through our comprehensive solutions designed to support the development, execution, and optimization of clinical trials.
We support clinical trials at every stage, from protocol development to close-out and reporting. We ensure that every trial is regulatory compliant, scientifically sound, and efficiently ran.
We are committed to advancing dermatology and aesthetic medicine to deliver impactful results for patients, sponsors, and the community.
Pilot Studies: Early Validation for Clinical Development
Maxeome supports pharmaceutical and biotech clients in conducting pilot studies that assess feasibility, safety, and early efficacy. These small-scale clinical trials help fine-tune your study design before full-scale implementation.
-
Feasibility and protocol testing
-
Early safety and tolerability data
-
Guidance on transitioning to larger trials
Evidence-First Mindset
We design and execute research that answers real clinical and regulatory questions to improve patient outcomes.
Agile, Boutique Model
Bespoke and personalized solutions. Our responsive team delivers exceptional service to meet all of your needs
Strategic Communication
We turn results into well-crafted messages for regulators, payers, practitioners, and patients.
Local & Global Knowledge
We understand Saudi Arabia’s and the region's regulatory landscape in addition to international standards.
Integrated Capabilities
From study start-up to publication, everything under one roof. No handoffs, no silos.
Case Study
Client
A mid-size pharmaceutical company
Challenge
The client was planning a Phase II trial for a dermatological indication. After assessing their protocol, we identified setbacks. The proposed methodology and primary endpoints did not align with previously successful trials for their indication. This posed a risk to both regulatory acceptance and the future comparability of their results.
Maxeome's Approach
We conducted a benchmark analysis of comparable trials and identified discrepancies in methodology, primary endpoints, timing of assessments, and outcome measures. In addition, we strengthened the statistical analysis plan to match standard practices and enable comparability for meta-analysis in future submissions.
Outcome
We helped the sponsor avoid costly redesigns and potential regulatory pushback later in development. The optimized endpoints and methodology ensured the data would be comparable to other studies in the field, reducing the risk of wasted resources on an underpowered or non-publishable trial. This early strategic input streamlined the trial planning process and mitigated regulatory risks.